Passage Bio Unveils Gene Therapy Advances for Neurodegenerative Diseases

Reuters

Jan 12

<a href="https://laohu8.com/S/PASG">Passage Bio</a> Unveils Gene Therapy Advances for Neurodegenerative Diseases

Passage Bio Inc. has released a corporate presentation detailing advancements in its clinical and preclinical programs targeting neurodegenerative diseases. The company is progressing a clinical-stage, one-time gene therapy, PBFT02, for frontotemporal dementia caused by progranulin gene (_GRN_) mutations (FTD-GRN). PBFT02 utilizes a proprietary AAV1 vector and is administered via a nonsurgical injection directly to the cerebrospinal fluid, aiming to restore progranulin protein levels. Interim data indicate durable and elevated CSF progranulin levels following treatment. PBFT02 has received Fast Track and Orphan Drug Designation. Additionally, Passage Bio is pursuing preclinical development of a differentiated gene therapy for Huntington’s disease. The company estimates its cash runway extends into the first quarter of 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602651208"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602651208\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602651208?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602651208","market":"us","top_or_hot":-1,"title":"Passage Bio Unveils Gene Therapy Advances for Neurodegenerative Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PASG\">Passage Bio</a> Unveils Gene Therapy Advances for Neurodegenerative Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Passage Bio Inc. has released a corporate presentation detailing advancements in its clinical and preclinical programs targeting neurodegenerative diseases. The company is progressing a clinical-stage, one-time gene therapy, PBFT02, for frontotemporal dementia caused by progranulin gene (_GRN_) mutations (FTD-GRN). PBFT02 utilizes a proprietary AAV1 vector and is administered via a nonsurgical injection directly to the cerebrospinal fluid, aiming to restore progranulin protein levels. Interim data indicate durable and elevated CSF progranulin levels following treatment. PBFT02 has received <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug Designation. Additionally, Passage Bio is pursuing preclinical development of a differentiated gene therapy for Huntington’s disease. The company estimates its cash runway extends into the first quarter of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Passage Bio Unveils Gene Therapy Advances for Neurodegenerative Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPassage Bio Unveils Gene Therapy Advances for Neurodegenerative Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PASG\">Passage Bio</a> Unveils Gene Therapy Advances for Neurodegenerative Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Passage Bio Inc. has released a corporate presentation detailing advancements in its clinical and preclinical programs targeting neurodegenerative diseases. The company is progressing a clinical-stage, one-time gene therapy, PBFT02, for frontotemporal dementia caused by progranulin gene (_GRN_) mutations (FTD-GRN). PBFT02 utilizes a proprietary AAV1 vector and is administered via a nonsurgical injection directly to the cerebrospinal fluid, aiming to restore progranulin protein levels. Interim data indicate durable and elevated CSF progranulin levels following treatment. PBFT02 has received <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug Designation. Additionally, Passage Bio is pursuing preclinical development of a differentiated gene therapy for Huntington’s disease. The company estimates its cash runway extends into the first quarter of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL59QFSF:1","article_id":"2602651208","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602651208","pubTimestamp":1768221343,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Passage Bio Inc. has released a corporate presentation detailing advancements in its clinical and preclinical programs targeting neurodegenerative diseases. The company is progressing a clinical-stage, one-time gene therapy, PBFT02, for frontotemporal dementia caused by progranulin gene  mutations . PBFT02 utilizes a proprietary AAV1 vector and is administered via a nonsurgical injection directly to the cerebrospinal fluid, aiming to restore progranulin protein levels. Interim data indicate durable and elevated CSF progranulin levels following treatment. PBFT02 has received Fast Track and Orphan Drug Designation. Additionally, Passage Bio is pursuing preclinical development of a differentiated gene therapy for Huntington’s disease. The company estimates its cash runway extends into the first quarter of 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PASG":"Passage Bio, Inc."},"translate_title":"Passage Bio揭示神经退行性疾病基因治疗进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PASG":0.9},"content_text":"Passage Bio Unveils Gene Therapy Advances for Neurodegenerative Diseases\n    \n\n        Passage Bio Inc. has released a corporate presentation detailing advancements in its clinical and preclinical programs targeting neurodegenerative diseases. The company is progressing a clinical-stage, one-time gene therapy, PBFT02, for frontotemporal dementia caused by progranulin gene (_GRN_) mutations (FTD-GRN). PBFT02 utilizes a proprietary AAV1 vector and is administered via a nonsurgical injection directly to the cerebrospinal fluid, aiming to restore progranulin protein levels. Interim data indicate durable and elevated CSF progranulin levels following treatment. PBFT02 has received Fast Track and Orphan Drug Designation. Additionally, Passage Bio is pursuing preclinical development of a differentiated gene therapy for Huntington’s disease. The company estimates its cash runway extends into the first quarter of 2027. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}